Uses of Taxel-CSC 80ml/2ml

This is an automatically translated article.


Taxel-CSC 80ml/2ml belongs to the group of anti-cancer drugs and acts on the immune system, with the main ingredient docetaxel. It is commonly indicated for the treatment of locally advanced or metastatic cancers of the breast, lung, head and neck, prostate, stomach, ovary, and cervix.

1. What effect does Taxel have?


Taxel-CSC drug 80ml/2ml has the main ingredient docetaxel, which is a xanthan derivative with anti-mitotic effects, acting specifically on the M phase in the process of cancer cell division. The mechanism of action of docetaxel is to bind specifically to the tubulin beta subunit of the tubulin microstructure, inhibiting the disassembly of the tubule microstructure to the monomer form, a process required to provide energy for the cycle. mitotic period. As a result, Docetaxel has anti-cancer cytostatic effects. Taxel-CSC drug 80ml/2ml is usually indicated in the following cases:
In combination with Doxorubicin and Cyclophosphamide for adjuvant treatment of operable or non-lymphoid breast cancer, locally developed breast cancer or previously untreated metastases. Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy. Combination of cisplatin for the treatment of locally advanced or metastatic unresectable lung cancer after failure of previous chemotherapy. In combination with prednisone or prednisolone in the treatment of metastatic hormone-resistant prostate cancer. Combination of cisplatin and 5-fluorouracil for the treatment of gastric adenocarcinoma, including cardial adenocarcinoma in patients who have not received prior metastatic chemotherapy. Combination of cisplatin and 5-fluorouracil for the treatment of locally advanced squamous cell carcinoma of the head and neck. Contraindications of Taxel-CSC 80ml/2ml include:
Patients with hypersensitivity to any component of the drug. The patient has a neutrophil count < 1500 cells/mm3. Patients with severe liver failure. Women who are pregnant or breastfeeding.

2. Dosage of Taxel-CSC 80ml/2ml:


Depending on the subjects and treatment goals, the dose of Taxel-CSC 80ml/2ml will be different, specifically as follows:
Infusion: 100 mg/m2 IV infusion in 1 hour. Before infusion 1 day should be used dexamethasone 8 mg x 2 times / day x 3-5 days. If neutrophils are low with fever or neutrophils are < 500/mm3 for more than 1 week and there is severe peripheral neuropathy, the dose should be reduced to 75 mg/m2. If these reactions persist, reduce to 55 mg/m2 or discontinue treatment. For patients with hepatic impairment, the dose should be reduced. The safety and efficacy of docetaxel in the treatment of nasopharyngeal carcinoma in children 1 month to 18 years of age have not been established. There are no special instructions for use for the elderly.

3. Side effects of Taxel-CSC 80ml/2ml:


In some patients when using Taxel-CSC 80ml/2ml may experience side effects such as:
Neutropenia. Hypersensitivity reactions: Flushing, local skin reactions, severe hypotension, bronchospasm and generalized rash. Erythema of the palms and soles, edema and peeling. Fluid retention: Pleural effusion and ascites. Acute respiratory failure, pneumonia, and interstitial lung disease have been reported to lead to mortality. In the presence of severe peripheral neurotoxicity, the dose should be reduced. Heart failure. Macular edema and visual impairment.

4. Precautions when using Taxel-CSC 80ml/20ml:


Some general notes when using Taxel-CSC 80ml/2ml include:
Do not use the drug when bilirubin is above the upper limit of normal. Contraception should be used in both men and women during treatment and for at least 6 months after stopping therapy. Concomitant use of docetaxel with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir and voriconazole should be avoided. Docetaxel should not be used during pregnancy, unless clearly indicated. It is not known whether docetaxel is excreted in human milk and therefore breast-feeding should be discontinued during docetaxel treatment. Above is all information about Taxel-CSC 80ml/2ml, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Taxel-CSC 80ml/2ml for home treatment because there may be unwanted side effects.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.

44 reads

Relating articles
  • khối u bàng quang ác tính
    Malignant bladder tumor

    Malignant bladder tumor or malignant bladder cancer is one of the common cancers in the urinary tract with a poor prognosis if detected late and the disease is already in an advanced stage, invasive tumor. In such cases, treatment of ...

    Readmore
  • Carcinoid
    Learn Carcinoids and neuroendocrine tumors and how to treat them

    Neuroendocrine tumors are tumors that begin to form in the digestive system, which can be life-threatening if treated at a late stage. Therefore, understanding the causes and symptoms of carcinoid tumors will help patients choose the appropriate treatment.

    Readmore
  • Erdafitinib
    Uses of Erdafitinib

    Erdafitinib is a prescription medicine indicated in the treatment of bladder cancer (carcinoma) that has metastasized or stage cancer that cannot be removed by surgery.

    Readmore
  • Brigatinib
    Brigatinib side effects

    Brigatinib, also known by its common name Alunbrig, is a drug commonly used in the treatment of cancer. Besides the effective effects that the drug brings, it also causes unwanted reactions.

    Readmore
  • u trung biểu mô ác tính
    Surgery and stages of malignant mesothelioma

    Surgery is one of the most effective treatments for malignant mesothelioma. So how is malignant mesothelioma surgery performed? What are the stages of malignant mesothelioma? The following article will provide essential information about surgery and stages of malignant mesothelioma

    Readmore